Zentalis Pharmaceuticals (ZNTL) News Today $4.47 +0.11 (+2.52%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 10:43 AM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJuly 25 at 2:49 PM | prnewswire.comKuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law FirmJuly 24 at 8:00 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJuly 12, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJuly 12, 2024 | marketbeat.comShort Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Decreases By 46.1%Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) was the target of a significant drop in short interest in the month of June. As of June 30th, there was short interest totalling 9,620,000 shares, a drop of 46.1% from the June 15th total of 17,840,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is currently 7.1 days.July 10, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJuly 7, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJuly 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJuly 1, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 30, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJune 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLJune 20, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Lowered to "Neutral" at UBS GroupUBS Group cut shares of Zentalis Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $28.00 to $5.00 in a report on Thursday.June 18, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Hold Rating from Jefferies Financial GroupJefferies Financial Group restated a "hold" rating and set a $6.00 price objective (down previously from $42.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday.June 18, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) PT Lowered to $25.00 at OppenheimerOppenheimer lowered their target price on Zentalis Pharmaceuticals from $50.00 to $25.00 and set an "outperform" rating on the stock in a research report on Tuesday.June 18, 2024 | globenewswire.comInvestigation Into Zentalis Pharmaceuticals, Inc. (ZNTL) Announced byHolzer & Holzer, LLCJune 18, 2024 | marketbeat.comWedbush Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) to UnderperformWedbush downgraded Zentalis Pharmaceuticals from a "neutral" rating to an "underperform" rating and cut their price objective for the stock from $15.00 to $4.00 in a report on Tuesday.June 18, 2024 | globenewswire.comZentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development ProgramJune 14, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Down 4.4% Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price Down 4.4%June 12, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Sets New 12-Month Low at $9.48Zentalis Pharmaceuticals (NASDAQ:ZNTL) Hits New 52-Week Low at $9.48June 12, 2024 | marketbeat.comVerition Fund Management LLC Sells 192,742 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Verition Fund Management LLC lowered its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 35.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 344,617 shares of the compaJune 7, 2024 | marketbeat.comSectoral Asset Management Inc. Decreases Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Sectoral Asset Management Inc. trimmed its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 98.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,355 shares of the company's stocJune 7, 2024 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have received an average rating of "Moderate Buy" from the seven ratings firms that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and four haveJune 3, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2024 | insidertrades.comInsider Selling: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) CFO Sells 9,597 Shares of StockMay 30, 2024 | marketbeat.comDecheng Capital LLC Takes Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Decheng Capital LLC purchased a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 2,099,583 shares of the company's stock, vMay 30, 2024 | globenewswire.comZentalis Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 29, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price Down 6.3%Zentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Down 6.3%May 29, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of DirectorsMay 28, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Up 4.3%Zentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Up 4.3%May 23, 2024 | globenewswire.comZentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual MeetingMay 23, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Down 6.7%Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Down 6.7%May 15, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $11.67Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $11.67May 14, 2024 | globenewswire.comZentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation SummitMay 13, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Down 5.3% Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Down 5.3%May 10, 2024 | insidertrades.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Diana Hausman Sells 3,356 SharesMay 10, 2024 | marketbeat.comQ2 2024 Earnings Forecast for Zentalis Pharmaceuticals, Inc. Issued By Leerink Partnrs (NASDAQ:ZNTL)Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Leerink Partnrs reduced their Q2 2024 EPS estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 7th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($0.May 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Zentalis Pharmaceuticals (ZNTL) and Paragon 28 (FNA)May 9, 2024 | markets.businessinsider.comBuy Rating on Zentalis Pharmaceuticals Amid High Expectations for Azeno Drug TrialsMay 9, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Zentalis Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:ZNTL)Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Stock analysts at Wedbush issued their Q1 2025 earnings per share estimates for Zentalis Pharmaceuticals in a report issued on Tuesday, May 7th. Wedbush analyst R. Driscoll expects that the company will post earnings of ($0.71) per sharMay 9, 2024 | markets.businessinsider.comBuy Rating on Zentalis Pharmaceuticals: Strategic Developments and Multi-Cancer Treatment Potential of AzenosertibMay 8, 2024 | marketbeat.comHC Wainwright Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $40.00HC Wainwright decreased their target price on shares of Zentalis Pharmaceuticals from $46.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday.May 8, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results, Beats Expectations By $0.91 EPSZentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) released its quarterly earnings data on Tuesday. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of ($0.77) by $0.91. During the same period last year, the company earned ($1.07) EPS.May 8, 2024 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals StockMay 7, 2024 | finance.yahoo.comZentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ...May 7, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $11.72Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $11.72May 7, 2024 | globenewswire.comZentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational ProgressMay 2, 2024 | ca.finance.yahoo.comZentalis Pharmaceuticals, Inc. (ZNTL)May 1, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 24, 2024 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Down 7.1%Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Down 7.1%April 21, 2024 | marketbeat.comFederated Hermes Inc. Has $32.73 Million Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Federated Hermes Inc. lifted its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 10.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,160,565 shares of the company's Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Nvidia insiders dumping shares (Ad)All the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can. To see Porter Stansberry's new AI prediction go here now. ZNTL Media Mentions By Week ZNTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZNTL News Sentiment▼0.370.61▲Average Medical News Sentiment ZNTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZNTL Articles This Week▼42▲ZNTL Articles Average Week Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PRLD News Today CYRX News Today IRWD News Today ARQT News Today IRON News Today COLL News Today BCYC News Today ANAB News Today CNTA News Today CRON News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZNTL) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
